Modification of Certain Terminology in Title 21
FDA proposes to replace gendered terms (e.g., 'women') with sex-based definitions in 21 CFR, affecting dietary supplement labeling references to pregnancy, lactation, and sex-specific claims.
Aforeworn detected this change in the Dietary-Supplement Labeling (FDA) space on July 5, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Low urgency. Supplement brands, contract manufacturers, private-label sellers, ingredient suppliers making sex-specific claims (e.g., 'for women's health') or referencing pregnancy/lactation. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Comment period ends 60 days after publication (approx. July 6, 2026). Final rule effective date TBD.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Dietary-Supplement Labeling (FDA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
FDA proposes to modify terminology in 21 CFR to align with Executive Order 14168, replacing 'women' with 'female' and similar changes in labeling requirements, health claims, and nutrient content claims.
Who it affects
Supplement brands, contract manufacturers, private-label sellers, ingredient suppliers making sex-specific claims (e.g., 'for women's health') or referencing pregnancy/lactation.
What you must do
Review current labeling for gendered terms and prepare to update to sex-based language if rule is finalized.
Deadline
Comment period ends 60 days after publication (approx. July 6, 2026). Final rule effective date TBD.
Never miss a change like this again
Aforeworn watches Dietary-Supplement Labeling (FDA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Dietary-Supplement Labeling (FDA)
- FDA Advisory No.2026-0162-A || Lifting the Advisory on the Registered Food Product LUXE SKIN BEAUTY TALKS L’ANNA Premium Oral Sunblock + Stem Cell Dietary Supplement “Public Health Warning Against the Purchase and Consumption of the Unregis - fda.gov.ph
- The Dietary Supplement Industry in the Time of Trump: Potential Opportunities and Pitfalls - Food and Drug Law Institute (FDLI)
- 60 Degrees Pharmaceuticals Signs Exclusive Patent License Agreement with Florida State University for Non-Prescription Use of Australian Chestnut Extract as a Botanical Supplement - GlobeNewswire
- After 4-year review, FDA shuts down attempt to regulate CBD as a supplement and asks Congress for help - AgencyIQ by POLITICO
- US FDA New Dietary Ingredient Notification Submissions in the Last 4 Years - CIRS Group